Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Vδ1 γδ T cells are key players in innate and adaptive immunity, particularly at mucosal interfaces such as the gut. An increase in circulating Vδ1 cells has long been observed in people with HIV-1, but remains poorly understood. We performed a comprehensive characterization of Vδ1 T cells in blood and duodenal intra-epithelial lymphocytes, obtained from endoscopic mucosal biopsies of 15 people with HIV-1 on antiretroviral therapy and 15 HIV-seronegative controls, in a substudy of the ANRS EP61 GALT study (NCT02906137). We deciphered the phenotype, functional profile, single-cell transcriptome and repertoire of Vδ1 cells and unraveled their relationships with the possible triggers involved, in particular CMV and microbiota. We also assessed whether Vδ1 T cells may play a role in controlling the HIV-1 reservoir. Vδ1 T cells were mainly terminally differentiated effectors that clonally expanded in the blood with some trafficking with the gut of people with HIV-1. Most expressed CX3CR1 and displayed a highly cytotoxic profile, but low cytokine production, supported by a transcriptomic shift towards enhanced effector lymphocytes. This expansion was associated with CMV status and markers of occult replication, but also with changes in the duodenal and blood-translocated microbiota. Cytotoxic, but not IFN-γ-producing, Vδ1 T cells were negatively associated with cell-associated HIV-1 RNA in both the blood and duodenal compartments. The increase in Vδ1 T cells observed in people with HIV-1 has multiple triggers, particularly CMV and microbiota, and may in turn contribute to the control of the HIV-1 reservoir.

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.ppat.1013489DOI Listing

Publication Analysis

Top Keywords

vδ1 cells
32
people hiv-1
16
cmv microbiota
12
vδ1
9
cells
9
hiv-1
8
antiretroviral therapy
8
observed people
8
blood duodenal
8
hiv-1 reservoir
8

Similar Publications

Impact of mistletoe lectin binding in breast cancer.

Anticancer Res

June 2004

Zentrum für diagnostische Medizin Robert Bosch Krankenhaus, Auerbachstr. 110, D-70376 Stuttgart, Germany.

Background: One of the most often used complementary or alternative anticancer therapeutics for breast cancer is mistletoe extract with Viscum album lectin (VAA-1) as the leading component. The aim of this study was to determine the correlation between VAA-1 binding in breast cancer and disease outcome.

Materials And Methods: VAA-1 binding to either tumour cells or tumour infiltrating inflammatory cells was examined by immunohistochemical staining of paraffin tissue sections from breast cancer patients (n=226).

View Article and Find Full Text PDF

Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells.

Anticancer Res

December 2001

Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, Germany.

Background: Viscum album agglutinin-1 (VAA-1) is assumed to be the biologically most active ingredient of misteltoe extracts that are often used as adjuvant cancer therapy. To develop new approaches for lung cancer treatment, we evaluated the antineoplastic activity of VAA-1 alone and in combination with other chemotherapeutic drugs, including doxorubicin, cisplatin and taxol in the human lung carcinoma cell line A549.

Materials And Methods: Cytotoxicity was determined by 5-bromo-2'-deoxyuridine (BrdU) ELISA-assays and drug interaction assessed by the isobologram method.

View Article and Find Full Text PDF

Modulating activity of mistletoe lectins 1 and 2 on the lymphatic system in BALB/c-mice.

Phytomedicine

January 1996

Institute of Medicinal Microbiology and Hygiene, University of Cologne, D-50935 Cologne, Goldenfelsstr. 19-21.

The galactoside-specific lectin (mistletoe lectin-1, VAA-1) and the N-acetylgalactosamine-specific lectin (mistletoe lectin-2, VAA-2) were purified from aqueous mistletoe extract and checked for their immunoactive potency. Regular subcutaneous administration of the optimal immunomodulating VAA-1 /VAA-2 dosage (1 ng lectin/kg body weight) could be shown to modulate thymocyte proliferation, maturation, emigration and activation in BALB/c-mice. Thus, the increase in thymocyte counts was statistically significant after VAA-1 treatment.

View Article and Find Full Text PDF